# GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

> **NCT04456998** · PHASE2 · COMPLETED · sponsor: **GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.** · enrollment: 86 (actual)

## Conditions studied

- Pulmonary Artery Hypertension

## Interventions

- **DRUG:** GB002 (seralutinib)
- **DRUG:** Placebo
- **DEVICE:** Generic Dry Powder Inhaler

## Key facts

- **NCT ID:** NCT04456998
- **Lead sponsor:** GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-12
- **Primary completion:** 2022-10-17
- **Final completion:** 2022-11-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456998, "GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04456998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*